Every biopharma company talks about putting the patient at the center of everything they do, incorporating the voice of the patient and being patient-centric. However, very few companies are actually doing it. Why is it so hard to conduct clinical development in a patient-centric manner? What actions can we take in 2019?
Social media is no longer just a conduit for digital advertising; instead, it has become a powerful tool that pharmaceutical companies use to identify, listen to, engage, and collaborate with patients to improve drug discovery, development, and utilization.
There is more investment in lupus drug development than ever before, bringing renewed hope that these investments will expand our knowledge of the disease and how it’s treated. A key reason for this renewed hope is the patient voice, a factor that is even more critical in lupus because the disease impacts each person differently.
Today’s clinical trial partner is tomorrow’s post-approval patient. They are the experts who can shape a program over time, be a voice during the regulatory approval process, and provide insight on what other patients hope to find in a therapy.
Can patient recruitment for clinical trials be more efficient with more involvement by patient relations and market access directors?
In 2014, an important dialogue was initiated between big pharma and big academia. The Janssen Pharmaceuticals Companies of J&J, Office of the Chief Medical Officer and the Division of Medical Ethics at NYU School of Medicine partnered to implement an innovative model to support their most important stakeholder — patients.
|
|
|
|
|
|
|
|
|